Page 2 - Pharma Medtech News Today

Shortfall a further blow to EU’s vaccination plans already hampered by repeated delays

Company to deliver 200m doses to EU with 600,000 to Republic between April and June

America will continue to be the focus. While Icon’s business is currently split evenly between the US and Europe (with the rest of the world accounting for 20 per cent), around two-thirds of all mandates come from US pharma companies. That reality is reflected in the fact that Cutler, like his predecessor Ciaran Murray is largely based over there. However, the acquisition will double Icon’s resources in the important Japanese market and in China. Where Icon previously had strategic pa...

EU has deal with company for millions of doses

No Covid-related deaths reported in the group vaccinated in clinical trial

Dublin clinical trials group Icon buys PRA in $12bn deal Combined group will form the world’s largest contract research organisation Wed, Feb 24, 2021, 11:31   Irish clinical trials group Icon, which employs more than 1,000 people in the Republic, is to acquire US company PRA Health Sciences in a $12 billion (€9.87 billion) deal. The combined company will form the world’s largest contract research organisation, and is to be headquartered at Icon’s Leopardstown campus in Dublin. The ca...

White House adviser says only a few million doses will be available at expected US approval date

Commission also putting funds into studying and responding to new variants of disease

Back pain device group Mainstay Medical raises $108m Funding will drive commercialisation of Reactiv8 in critical US market Tue, Feb 16, 2021, 13:00 Updated: Tue, Feb 16, 2021, 18:24 Irish company Mainstay Medical has developed a device to address chronic lower back pain Your Web Browser may be out of date. If you are using Internet Explorer 9, 10 or 11 our Audio player will not work properly.   Irish company Mainstay Medical, which has developed a device to address chronic lower b...

EMA expects Johnson & Johnson to file for vaccine approval within days New BioNTech production site will have capacity to produce 750m doses annually Fri, Feb 12, 2021, 17:04 Updated: Fri, Feb 12, 2021, 21:26 The first stage of BioNTech’s vaccine process, producing the active ingredient known as mRNA, has begun at a new plant in Marburg. Photograph: AFP via Getty   The European Medicines Agency (EMA) expects Johnson & Johnson to file for approval of its Covid-19vaccine in the EU wit...